Veregen Topical Ointment 15pct Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • myWeekly Ad

Veregen: Topical ointment (15%)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file default-drug-image.png
Veregen 15% Topical Ointment
Drug Image file default-drug-image.png
Veregen 15% Topical Ointment

What is this Medicine?

SINECATECHINS is made from green tea leaves. It is used to treat external genital or anal warts. This medicine is not a cure. New warts may appear during or after treatment.

CVS Pharmacy Patient Statistics for Veregen: Topical ointment(15%)
Generic vs. Brand Name Usage*
*Brand contains same active ingredient but may not represent FDA-approved generic equivalent
Usage By Strength
In-Depth Information

Veregen 15% Topical Ointment

NDC: 103370450
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Condylomata Acuminata

Storage Information
After dispensing, store refrigerated or up to 77 degrees F
Do not freeze
Prior to dispensing, store in refrigerator (36 to 46 degrees F)
Veregen 15% Topical Ointment

Reported Side Effects for Veregen 15% Topical Ointment

Superinfection Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Skin Necrosis Incidence:
<1.0%*
Severity: SEVERE
Onset: EARLY
Skin Irritation Incidence:
<1.0%*
Severity: MILD
Onset: EARLY
Skin Discoloration Incidence:
<1.0%*
Severity: MILD
Onset: DELAYED
Pelvic Pain Incidence:
<1.0%*
Severity: MILD
Onset: DELAYED
Hyperesthesia Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Abnormal Cervical Cells Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Infection Incidence:
<1.0%*
Severity: MILD
Onset: DELAYED
Skin Rash Incidence:
1.0%*
Severity: MILD
Onset: EARLY
Bleeding Incidence:
2.0%*
Severity: MODERATE
Onset: EARLY
Enlarged Lymph Nodes Incidence:
3.0%*
Severity: MODERATE
Onset: DELAYED
Phimosis Incidence:
3.0%*
Severity: SEVERE
Onset: DELAYED
Vesicular Rash Incidence:
20.0%*
Severity: MILD
Onset: DELAYED
Swelling Incidence:
45.0%*
Severity: MODERATE
Onset: DELAYED
Skin Ulcer Incidence:
49.0%*
Severity: MODERATE
Onset: DELAYED
Skin Ulcer Incidence:
49.0%*
Severity: MODERATE
Onset: DELAYED
Itching Incidence:
69.0%*
Severity: MILD
Onset: RAPID
Skin Redness Incidence:
70.0%*
Severity: MODERATE
Onset: EARLY
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
FIRST Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

SECOND Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

THIRD Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

Lactation

Compatible - This drug is generally safe to take by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Veregen

We want to help you stay educated about the medications you are taking. View other
patient's observations and share your own.

Be sure to consult your health care provider before taking any medications. Other
patient's comments should not be considered medical advice or health care provider
recommendations.